Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 25 September 2007
Vol. 2007, Issue 405, p. pe53
[DOI: 10.1126/stke.4052007pe53]

PERSPECTIVES

Interferon at 50: New Molecules, New Potential, New (and Old) Questions

Jerome A. Langer*

Department of Molecular Genetics, Microbiology, and Immunology, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, 675 Hoes Lane West, Piscataway, NJ 08854, USA.

Abstract: Type I interferons (IFNs) are a family of cytokines defined by their antiviral activity but with a broad spectrum of biological activities, including antiproliferative, antitumor, and immunomodulatory effects. Mirroring these activities are diverse therapeutic applications to viral infections, antitumor therapy, and multiple sclerosis. The type I IFNs all signal through a common heterodimeric receptor. The existence of such a large family of cytokines (17 human IFNs) activating a common receptor is unusual. Moreover, the IFNs vary in their relative potency in different assays and are not functionally equivalent. How this functional variation is mediated through a common receptor has not been understood. Reports have now highlighted the interaction of IFNs with the low-affinity receptor subunit IFNAR-1 as a surprising key to their differential activity, particularly regarding antiproliferative and antitumor activities. Two groups have used contrasting approaches to produce variant IFN-{alpha} proteins with novel activity profiles. These advances portend enhanced therapeutic possibilities based on the better understanding of IFN-receptor interactions, while raising interesting mechanistic questions.

*Corresponding author: E-mail, langer{at}umdnj.edu

Citation: J. A. Langer, Interferon at 50: New Molecules, New Potential, New (and Old) Questions. Sci. STKE 2007, pe53 (2007).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882